These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://phoenixivgo847958.blogzag.com/82466355/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide